Business Context and Reporting Period
Company: Niagen Bioscience, Inc. (formerly ChromaDex Corporation)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and nine months ended September 30, 2025
Business Overview: A global bioscience company focused on healthy aging, primarily through the development and commercialization of NAD+ precursors, specifically nicotinamide riboside chloride (Niagen®). The company operates three segments: Consumer Products (Tru Niagen®), Ingredients (food and pharmaceutical-grade Niagen®), and Analytical Reference Standards and Services.
Key Financial Metrics
| Financial Metric (in thousands) | 3 Months Ended Sept 30, 2025 | 9 Months Ended Sept 30, 2025 | 9 Months Ended Sept 30, 2024 |
|---|---|---|---|
| Net Sales | $33,986 | $95,584 | $70,472 |
| Gross Profit | $21,928 | $61,485 | $43,389 |
| Gross Margin | 64.5% | 64.3% | 61.6% |
| Operating Income | $4,236 | $12,193 | $615 |
| Net Income | $4,578 | $13,250 | $1,371 |
| Diluted EPS | $0.05 | $0.15 | $0.02 |
| Cash from Operating Activities | N/A | $12,825 | $3,526 |
| Cash and Cash Equivalents (Sept 30, 2025) | $64,290 | ||
| Total Liabilities (Sept 30, 2025) | $27,463 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 33% year-over-year for the quarter and 36% for the nine-month period. The Consumer Products segment drove this growth with a 44% quarterly increase, primarily due to e-commerce performance and distributor sales. The Ingredients segment saw a 63% increase for the nine-month period.
- Profitability: The company achieved significant profitability improvements. Operating income rose from $1.6 million to $4.2 million for the quarter and from $0.6 million to $12.2 million for the nine-month period. Net income for the nine months ended September 30, 2025, was $13.3 million compared to $1.4 million in the prior year.
- Margin Expansion: Gross margin improved by approximately 270 basis points for the nine-month period, driven by favorable product mix shifts and lower-cost inventory purchases. Sales and marketing expenses as a percentage of net sales decreased, indicating improved efficiency.
- Legal Settlement Recovery: The company recorded a recovery of credit losses of approximately $1.2 million (reflected in the cash flow statement) related to the settlement of the California Action against Elysium Health, LLC. The full settlement of $2.65 million was received in late 2024 and early 2025.
- Inventory Build: Inventories increased significantly from $9.2 million to $18.8 million, reflecting a strategic build-up to meet future demand and purchase commitments.
Guidance, Outlook, Risks, and Unusual Items
- Liquidity Outlook: Management anticipates that current unrestricted cash ($64.1 million) and cash generated from operations will be sufficient to meet obligations for at least the next 12 months. However, the company may seek additional capital to fund long-term strategic objectives.
- Supply Chain Commitments: The company executed a new Sales Agreement with W.R. Grace & Co.-Conn (Grace) requiring the purchase of approximately $33.6 million in inventory through September 30, 2026. Grace remains the sole supplier for the key ingredient NRC.
- Legal Contingencies:
- Elysium Health (Delaware Action): The company is appealing a judgment requiring it to pay approximately $9.2 million in fees and costs (plus interest, totaling approx. $10.4 million). Management believes the court abused its discretion and has not accrued a liability, but acknowledges a contingent liability exists if the appeal fails.
- Class Action Lawsuit: A class action lawsuit was filed in October 2025 regarding automatic renewal disclosures. The company believes the allegations lack merit and does not expect a material impact.
- Executive Compensation: CEO Robert Fried received a grant of 1.5 million market performance stock units (PSUs) in February 2025, subject to a seven-year performance period.
- Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 made permanent certain tax provisions. The company does not anticipate a significant impact on its effective tax rate or valuation allowance.
Investor Verification Checklist
- Customer Concentration: Verify the stability of relationships with major customers, specifically A.S. Watson Group (39% of trade receivables) and Life Extension (14.7% of trade receivables), which collectively represent a significant portion of receivables.
- Legal Appeal Outcome: Monitor the status of the appeal regarding the Delaware patent infringement action against Elysium Health, where a potential liability of ~$10.4 million is at stake.
- Inventory Turnover: Assess the company's ability to sell the significant inventory build-up ($18.8 million) against the $33.6 million purchase commitment to W.R. Grace.
- Regulatory Environment: Track FDA decisions regarding NAD+ precursors, specifically the status of NMN as a dietary ingredient and the regulatory pathway for pharmaceutical-grade Niagen®.
- Capital Needs: Evaluate the necessity of future equity or debt financing given the history of operating losses (accumulated deficit of $168.7 million) despite recent quarterly profitability.